BioCentury | Jul 8, 2017
Finance

A clinical quarter

...MAA and NDA Mid-2017 Celgene Corp. (NASDAQ:CELG) Ozanimod Relapsing multiple sclerosis (MS) Submit NDA YE17 Cerenis...
BioCentury | Apr 7, 2017
Finance

Fade to black

...develop and commercialize the arginase 1 (ARG1) and ARG2 inhibitor CB-1158 in hematology and oncology. Cerenis...
...Mass. Argos Therapeutics Inc. (NASDAQ:ARGS), Durham, N.C. Calithera Biosciences Inc. (NASDAQ:CALA), South San Francisco, Calif. Cerenis...
...NASDAQ:VRTX), Boston, Mass. Amran Gowani, Senior Editor, Research & Analytics CB-1158 CER-001 Cologuard Etuary NKTR-181 tezacaftor (VX-661)/ivacaftor volanesorsen AMAG Pharmaceuticals Inc. Argos Therapeutics Inc. Calithera Biosciences Inc. Cerenis...
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

...NASDAQ:CELG) Ozanimod Relapsing MS Ph III RADIANCE and SUNBEAM data 1H17 Cerenis Therapeutics S.A. (Euronext:CEREN) Cerenis...
BioCentury | Jan 18, 2016
Clinical News

Cerenis HDL: Phase III started

...CER-001 for 48 weeks in about 30 patients. Cerenis Therapeutics S.A. (Euronext:CEREN), Labege, France Product: Cerenis...
BioCentury | Dec 17, 2015
Distillery Therapeutics

Therapeutics: Peroxisome proliferation activated receptor delta (PPARδ)

...PPARδ agonist, in Phase I and Phase II testing to treat cirrhosis, dyslipidemia and hypercholesterolemia. Cerenis...
BioCentury | Aug 3, 2015
Clinical News

Cerenis HDL: Phase II data

...Phase II CARAT trial of 3 mg/kg CER-001. Cerenis Therapeutics S.A. (Euronext:CEREN), Labege, France Product: Cerenis...
BioCentury | May 11, 2015
Finance

Debuting Biocartis

...S.A. (Euronext:ADOC; Pink:ADOCY) 2/14/12 $36.3 -2% 306% Pixium Vision S.A. (Euronext:PIX) 6/17/14 $53.4 -3% -23% Cerenis...
BioCentury | Apr 6, 2015
Finance

Fundamental rally

...Post-$ 3/31 cap % chg SanBio Co. Ltd. (Tokyo:4592) (A) 3/30/15 $67.2 $732.8 NA NA Cerenis...
BioCentury | Mar 30, 2015
Financial News

Cerenis Therapeutics S.A completes IPO

Cerenis Therapeutics S.A . (Euronext:CEREN), Labege, France Business: Cardiovascular, Endocrine/Metabolic Date completed: 2015-03-26 Type: IPO Raised: EUR53.4 million ($57.7 million) Shares: 4.2 million Price: EUR12.70 Shares after offering: 17.8 million Underwriters: CM-CIC Securities; Gilbert Dupont Overallotment:...
BioCentury | Mar 27, 2015
Financial News

Cerenis raises EUR 53.4M in Euronext IPO

...Cardiovascular play Cerenis Therapeutics S.A. (Euronext:CEREN) raised EUR 53.4 million ($57.7 million) through the sale of...
...Securities and Gilbert Dupont were underwriters. Cerenis expects its shares to begin trading March 30. Cerenis...
...transporter 1 ( ABCA1 ) deficiencies. Cerenis' investors include Sofinnova Partners, which said it remains Cerenis'...
Items per page:
1 - 10 of 57
BioCentury | Jul 8, 2017
Finance

A clinical quarter

...MAA and NDA Mid-2017 Celgene Corp. (NASDAQ:CELG) Ozanimod Relapsing multiple sclerosis (MS) Submit NDA YE17 Cerenis...
BioCentury | Apr 7, 2017
Finance

Fade to black

...develop and commercialize the arginase 1 (ARG1) and ARG2 inhibitor CB-1158 in hematology and oncology. Cerenis...
...Mass. Argos Therapeutics Inc. (NASDAQ:ARGS), Durham, N.C. Calithera Biosciences Inc. (NASDAQ:CALA), South San Francisco, Calif. Cerenis...
...NASDAQ:VRTX), Boston, Mass. Amran Gowani, Senior Editor, Research & Analytics CB-1158 CER-001 Cologuard Etuary NKTR-181 tezacaftor (VX-661)/ivacaftor volanesorsen AMAG Pharmaceuticals Inc. Argos Therapeutics Inc. Calithera Biosciences Inc. Cerenis...
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

...NASDAQ:CELG) Ozanimod Relapsing MS Ph III RADIANCE and SUNBEAM data 1H17 Cerenis Therapeutics S.A. (Euronext:CEREN) Cerenis...
BioCentury | Jan 18, 2016
Clinical News

Cerenis HDL: Phase III started

...CER-001 for 48 weeks in about 30 patients. Cerenis Therapeutics S.A. (Euronext:CEREN), Labege, France Product: Cerenis...
BioCentury | Dec 17, 2015
Distillery Therapeutics

Therapeutics: Peroxisome proliferation activated receptor delta (PPARδ)

...PPARδ agonist, in Phase I and Phase II testing to treat cirrhosis, dyslipidemia and hypercholesterolemia. Cerenis...
BioCentury | Aug 3, 2015
Clinical News

Cerenis HDL: Phase II data

...Phase II CARAT trial of 3 mg/kg CER-001. Cerenis Therapeutics S.A. (Euronext:CEREN), Labege, France Product: Cerenis...
BioCentury | May 11, 2015
Finance

Debuting Biocartis

...S.A. (Euronext:ADOC; Pink:ADOCY) 2/14/12 $36.3 -2% 306% Pixium Vision S.A. (Euronext:PIX) 6/17/14 $53.4 -3% -23% Cerenis...
BioCentury | Apr 6, 2015
Finance

Fundamental rally

...Post-$ 3/31 cap % chg SanBio Co. Ltd. (Tokyo:4592) (A) 3/30/15 $67.2 $732.8 NA NA Cerenis...
BioCentury | Mar 30, 2015
Financial News

Cerenis Therapeutics S.A completes IPO

Cerenis Therapeutics S.A . (Euronext:CEREN), Labege, France Business: Cardiovascular, Endocrine/Metabolic Date completed: 2015-03-26 Type: IPO Raised: EUR53.4 million ($57.7 million) Shares: 4.2 million Price: EUR12.70 Shares after offering: 17.8 million Underwriters: CM-CIC Securities; Gilbert Dupont Overallotment:...
BioCentury | Mar 27, 2015
Financial News

Cerenis raises EUR 53.4M in Euronext IPO

...Cardiovascular play Cerenis Therapeutics S.A. (Euronext:CEREN) raised EUR 53.4 million ($57.7 million) through the sale of...
...Securities and Gilbert Dupont were underwriters. Cerenis expects its shares to begin trading March 30. Cerenis...
...transporter 1 ( ABCA1 ) deficiencies. Cerenis' investors include Sofinnova Partners, which said it remains Cerenis'...
Items per page:
1 - 10 of 57